AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

AstraZeneca inks strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research: Cambridge, UK Saturday, June 14, 2025, 09:00 Hrs [IST] AstraZeneca has entered a ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

The collaboration aims to advance the discovery and development of novel oral candidates.

Anglo-Swedish pharma major AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC ...

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 ...